The Study by prof. EVANS on Q10 UNIQUINOL 2007

Similar evidence of superior bioavailability of UBIQUINOL compared to IUNIQUINONE was found in targeted studies, specifically in the cardiovascular area: in 2008, Langsjoen reported data on patients in therapy at its clinical department for heart failure. The subjects were stably undergoing traditional ubiquinone treatment. The researcher has decided to switch to the innovative UBIQUINOL, adapting patient dosages in the way he thinks fit.

Lo studio del prof. EVANS con Q10 UNICHINOLO 2007